Drugs / Glargine U300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03013985 | May 2017 → Mar 2019 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glargine U300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03013985 ↗ |
| Modality | Protein / enzyme biologic | “Glargine U300 is a new generation long-acting insulin.” NCT03013985 ↗ |